BioSpace News Archive

Overview of clinical and nonclinical data to date for oliceridine; includes efficacy data in hard- and soft- tissue surgeries, safety / tolerability data in high-risk patients

MedMira Inc., announced that it had submitted the notification for the Emergency Use Authorization application offered by the U.S. Food and Drug Administration for its newest member of its Reveal line of products for antibody testing.

CareDx and Johns Hopkins Announce Mobile Health Partnership with RemoTraC Use Among Lung Transplant Patients

During the ongoing COVID-19 pandemic, people across Texas are facing challenges that extend beyond medical care and include basic daily needs such as food and essential supplies.

Bausch Health Companies Inc. will release its first-quarter 2020 financial results on Thursday, May 7, 2020.

Yiling Pharmaceutical announced that Lianhua Qingwen capsules have been added to the “Novel Coronavirus Pneumonia Diagnosis and Treatment Scheme for Laos” as the fourth traditional Chinese medicine to treat COVID-19 pneumonia in Laos.

Covalon Technologies Ltd., an advanced medical technologies company, is delighted to announce that Mr. Martin Goldfarb has joined its Board of Directors..

Audax Medical, Inc. has secured an exclusive worldwide license from Northeastern University for an advanced nanomolecular technology addressing the development of COVID-19 and other anti-viral therapies. In collaboration with Dr. Thomas Webster , Art Zafiropoulo Chair and Professor of Chemical Engineering at Northeastern Univers

miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced it will report its first quarter 2020 financial results after the financial markets close on Thursday, May 7, 2020. The Company’s management team is scheduled to host a conference call and webcast at 4:30 p.m. ET on Thursday, May 7, 2020. To access the call, please dial 87

Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced it entered into a $15 million common stock purchase agreement and registration rights agreement with Lincoln Park Capital Fund, LLC (“LPC”), a Chicago-based institutional investor. Under the terms and conditions of the purchase agreement, Daré will have the right, from time to time and at its sole discretion, to sell up to $15 million of its stock to LP